Literature DB >> 7533443

High-affinity specific [3H]tamsulosin binding to alpha 1-adrenoceptors in human prostates with benign prostatic hypertrophy.

S Yamada1, C Tanaka, T Ohkura, R Mori, R Kimura, O Inagaki, K Honda, K Kawabe.   

Abstract

The binding of a novel radioligand, [3H]tamsulosin, to human prostatic membranes with benign prostatic hypertrophy (BPH) has been characterized. [3H]Tamsulosin rapidly associated with its binding sites in human prostatic membranes with BPH, and the binding reached steady state by 30 min at 25 degrees C. The rate constants for association and dissociation of [3H]tamsulosin binding were calculated to be 0.21 +/- 0.05/nM per minute and 0.01 +/- 0.004/min, respectively. The specific binding of [3H]tamsulosin in human prostatic membranes was saturable and of high affinity (Kd = 0.04 +/- 0.01 nM). The density of [3H]tamsulosin-binding sites (Bmax) was 409 +/- 28 fmol/mg protein. The Kd and Bmax values for [3H]tamsulosin binding in human prostates were significantly lower than those for [3H]prazosin binding. [3H]tamsulosin binding was remarkable for its significantly lower degree of nonspecific binding. Six alpha-adrenoceptor antagonists competed with [3H]tamsulosin for the binding sites in the rank order: tamsulosin > WB4101 > prazosin > S-(+)-isomer > naftopidil > yohimbine. The binding affinities (pKi) of these antagonists for [3H]tamsulosin binding in human prostates closely correlated with their pharmacological potencies (pA2) in prostates. In conclusion, [3H]tamsulosin selectively labels alpha 1-adrenoceptors in human prostates, and thus may become a useful radioligand for the further analysis of these receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7533443     DOI: 10.1007/bf00297194

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  27 in total

1.  In vitro characterization of the alpha-adrenoceptors in human prostate.

Authors:  J P Hieble; M Caine; E Zalaznik
Journal:  Eur J Pharmacol       Date:  1985-01-02       Impact factor: 4.432

2.  Density and localization of alpha 1-adrenoceptors in hypertrophied prostate.

Authors:  K Kawabe; N Moriyama; K Hamada; T Ishima
Journal:  J Urol       Date:  1990-03       Impact factor: 7.450

3.  Dynamics of acute retention in prostatic patient and role of adrenergic receptors.

Authors:  M Caine; S Perlberg
Journal:  Urology       Date:  1977-04       Impact factor: 2.649

4.  Autonomic innervation of the human prostate.

Authors:  A Vaalasti; A Hervonen
Journal:  Invest Urol       Date:  1980-01

5.  [3H]bunazosin, a novel selective radioligand of alpha 1 adrenoceptors in human prostates.

Authors:  S Yamada; M Suzuki; Y Matsuoka; Y Kato; R Kimura; M Maruyama; K Kawabe
Journal:  J Urol       Date:  1991-09       Impact factor: 7.450

6.  Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5.

Authors:  J W Lomasney; S Cotecchia; W Lorenz; W Y Leung; D A Schwinn; T L Yang-Feng; M Brownstein; R J Lefkowitz; M G Caron
Journal:  J Biol Chem       Date:  1991-04-05       Impact factor: 5.157

7.  Characterization of [3H]YM617, R-(-)-5-[2-[[2[ethoxyring(n)-3H](o-ethoxyphenoxy)ethyl]amino]- propyl]-2-methoxybenzenesulfonamide HCl, a potent and selective alpha-1 adrenoceptor radioligand.

Authors:  H Yazawa; M Takanashi; K Sudoh; O Inagaki; K Honda
Journal:  J Pharmacol Exp Ther       Date:  1992-10       Impact factor: 4.030

8.  Alpha 1 adrenoceptor subtypes in the human prostate.

Authors:  H Lepor; R Tang; S Meretyk; E Shapiro
Journal:  J Urol       Date:  1993-03       Impact factor: 7.450

9.  The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle.

Authors:  H Lepor; R Tang; E Shapiro
Journal:  Prostate       Date:  1993       Impact factor: 4.104

10.  Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate.

Authors:  K Honda; C Nakagawa
Journal:  J Pharmacol Exp Ther       Date:  1986-11       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.